Agilent Restructures for Market Focus, Bolsters Life Sciences & Diagnostics

TL;DR

**Agilent's strategic realignment is a bullish signal, positioning the company for accelerated growth in high-demand life science and diagnostics sectors.**

AI Summary

Agilent Technologies, Inc. (A) reported a significant organizational restructuring in November 2024, consolidating its Diagnostics and Genomics segment with liquid chromatography and mass spectrometry platforms into a new Life Sciences and Diagnostics Markets segment. Its chemistries, supplies, lab automation, and software moved to the Agilent CrossLab segment, while gas chromatography, spectroscopy, and vacuum divisions formed the new Applied Markets segment. The company, a global leader in life sciences, diagnostics, and applied markets, provides application-focused solutions including instruments, software, services, and consumables. As of October 31, 2025, Agilent employed approximately 18,100 people worldwide. The Life Sciences and Diagnostics Markets segment, employing 6,300 people, focuses on pharmaceutical, biopharmaceutical, diagnostics, clinical, academic, and government markets, offering specialized contract development and manufacturing services for pharmaceutical customers and solutions for cellular and molecular sample interrogation. The company's market capitalization was approximately $26.6 billion as of April 30, 2025, with 283,498,871 shares outstanding as of December 10, 2025.

Why It Matters

Agilent's strategic reorganization into three distinct segments – Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets – is a critical move to sharpen its market focus and enhance customer-centricity. This restructuring could streamline operations, improve resource allocation, and accelerate innovation in key growth areas like biopharmaceuticals and diagnostics, directly impacting investors through potential margin expansion and increased market share. For employees, it signifies a clearer strategic direction and potential shifts in team structures. Customers stand to benefit from more tailored solutions and improved service delivery, especially in the rapidly evolving life sciences and clinical diagnostics competitive landscape, where companies like Thermo Fisher Scientific and Danaher are also vying for market dominance.

Risk Assessment

Risk Level: medium — The company's forward-looking statements acknowledge risks including macroeconomic conditions, foreign currency fluctuations, and the integration of acquisitions, as detailed in Part I Item 1A. While the restructuring aims for efficiency, any significant organizational change carries execution risk, potentially impacting short-term operational performance and financial results. The global nature of Agilent's operations, with approximately 18,100 employees worldwide and manufacturing sites across multiple continents, exposes it to geopolitical and supply chain vulnerabilities.

Analyst Insight

Investors should monitor Agilent's upcoming earnings reports for evidence of successful integration and improved segment performance following the November 2024 reorganization. Focus on the growth trajectory of the new Life Sciences and Diagnostics Markets segment, as this is a key strategic area. Consider holding existing positions, but be prepared to re-evaluate if the restructuring fails to deliver anticipated operational efficiencies or market share gains.

Financial Highlights

debt To Equity

N/A

revenue

$N/A

operating Margin

N/A

total Assets

$N/A

total Debt

$N/A

net Income

$N/A

eps

$N/A

gross Margin

N/A

cash Position

$N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $26.6B — Market Capitalization (Aggregate market value of common equity held by non-affiliates as of April 30, 2025.)
• 283.5M — Outstanding Shares (Total common stock shares as of December 10, 2025.)
• 18,100 — Global Employees (Total employees worldwide as of October 31, 2025, indicating global operational scale.)
• 6,300 — LSDM Employees (Employees in the Life Sciences and Diagnostics Markets segment as of October 31, 2025, highlighting focus on this key segment.)
• 3 — New Business Segments (Number of new reportable segments after the November 2024 reorganization, indicating strategic realignment.)

Key Players & Entities

• Agilent Technologies, Inc. (company) — registrant
• Delaware (regulator) — state of incorporation
• New York Stock Exchange (regulator) — exchange for common stock
• $26.6 billion (dollar_amount) — aggregate market value of common equity held by non-affiliates as of April 30, 2025
• 283,498,871 (dollar_amount) — outstanding shares of common stock as of December 10, 2025
• October 31, 2025 (date) — fiscal year end
• November 2024 (date) — announcement of organizational structure change
• 18,100 (dollar_amount) — total employees worldwide as of October 31, 2025
• 6,300 (dollar_amount) — employees in Life Sciences and Diagnostics Markets segment as of October 31, 2025
• BIOVECTRA (company) — part of specialty CDMO offerings

FAQ

Risk Factors

• Cybersecurity Threats [medium — operational]: The company is exposed to risks associated with cybersecurity, including potential disruptions to operations, data breaches, and reputational damage. The increasing sophistication of cyberattacks necessitates continuous investment in security measures and incident response capabilities.
• Market Competition [medium — market]: Agilent operates in highly competitive markets for life sciences, diagnostics, and applied markets. Intense competition from other global players can impact market share, pricing power, and profitability.
• Regulatory Compliance [medium — regulatory]: The company's products and services are subject to various regulatory requirements in different jurisdictions, particularly in the diagnostics and pharmaceutical sectors. Failure to comply with these regulations could result in penalties, product recalls, or market access restrictions.
• Supply Chain Disruptions [medium — operational]: Agilent relies on a global supply chain for its manufacturing and distribution. Disruptions due to geopolitical events, natural disasters, or supplier issues could impact product availability and lead times.

Industry Context

Agilent Technologies operates in the dynamic life sciences, diagnostics, and applied markets sectors. These industries are characterized by rapid technological advancements, increasing demand for personalized medicine and advanced diagnostics, and stringent regulatory oversight. Key trends include the growth of biopharmaceutical research and development, the expansion of clinical testing capabilities, and the need for precise analytical instruments in environmental and food safety applications.

Regulatory Implications

Agilent's operations, particularly in the diagnostics and pharmaceutical markets, are subject to rigorous regulatory scrutiny by bodies like the FDA. Compliance with evolving regulations regarding product safety, efficacy, and data integrity is critical. The company must also navigate international regulatory landscapes, which can add complexity and cost to market access.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2024-11-01: Organizational Restructuring Announced — The company announced a significant reorganization, consolidating segments to better align with market-focused, customer-centric strategies. This impacts how financial results will be reported going forward.

Glossary

Life Sciences and Diagnostics Markets

A newly formed business segment combining former Diagnostics and Genomics with liquid chromatography and mass spectrometry platforms. (Represents a key strategic focus area for Agilent, serving critical research and clinical markets.)

Agilent CrossLab

A segment encompassing chemistries, supplies, laboratory automation, and software, designed to span the entire lab workflow. (This segment provides essential consumables and services that complement Agilent's instrument offerings and drive recurring revenue.)

Applied Markets

A new segment formed from gas chromatography, spectroscopy, and vacuum divisions. (This segment serves diverse industrial and environmental testing markets, providing analytical solutions.)

OFS (Order Fulfillment and Supply Chain)

Centralized operations responsible for manufacturing, engineering, and strategic sourcing. (Ensures efficient product delivery and cost management across Agilent's businesses.)

Year-Over-Year Comparison

The provided text focuses on the current fiscal year and a significant organizational restructuring announced in November 2024. Therefore, a direct comparison of key metrics like revenue growth, margin changes, or new risks to the previous year's filing is not possible with the information given. The restructuring itself represents a major strategic shift that will likely influence future financial reporting and performance comparisons.

Key Financial Figures

• $0.01 — ange on which registered Common Stock, $0.01 par value A New York Stock Exchange S

Filing Documents

• a-20251031.htm (10-K) — 3620KB
• a-10312025xexx1023.htm (EX-10.23) — 159KB
• a-10312025xexx1024.htm (EX-10.24) — 231KB
• a-10312025xexx1025.htm (EX-10.25) — 161KB
• a-10312025xexx211.htm (EX-21.1) — 8KB
• a-10312025xexx231.htm (EX-23.1) — 2KB
• a-10312025xexx311.htm (EX-31.1) — 11KB
• a-10312025xexx312.htm (EX-31.2) — 11KB
• a-10312025xexx321.htm (EX-32.1) — 6KB
• a-10312025xexx322.htm (EX-32.2) — 6KB
• a-20251031_g1.jpg (GRAPHIC) — 129KB
• 0001090872-25-000087.txt ( ) — 20906KB
• a-20251031.xsd (EX-101.SCH) — 78KB
• a-20251031_cal.xml (EX-101.CAL) — 91KB
• a-20251031_def.xml (EX-101.DEF) — 815KB
• a-20251031_lab.xml (EX-101.LAB) — 1346KB
• a-20251031_pre.xml (EX-101.PRE) — 1106KB
• a-20251031_htm.xml (XML) — 4106KB

Forward-Looking Statements

Forward-Looking Statements 3 PART I Item 1

Business

Business 3 Item 1A

Risk Factors

Risk Factors 18 Item 1B Unresolved Staff Comments 30 Item 1C Cybersecurity 30 Item 2

Properties

Properties 31 Item 3

Legal Proceedings

Legal Proceedings 31 Item 4 Mine Safety Disclosures 31 PART II Item 5 Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities 32 Item 6 [Reserved] 34 Item 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 34 Item 7A

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 59 Item 8

Financial Statements and Supplementary Data

Financial Statements and Supplementary Data 61 Item 9 Changes in and Disagreements with Accountants on Accounting and Financial Disclosure 123 Item 9A

Controls and Procedures

Controls and Procedures 123 Item 9B Other Information 123 Item 9C Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 123 PART III Item 10 Directors, Executive Officers and Corporate Governance 124 Item 11

Executive Compensation

Executive Compensation 124 Item 12

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 124 Item 13 Certain Relationships and Related Transactions, and Director Independence 125 Item 14 Principal Accounting Fees and Services 125 PART IV Item 15 Exhibits and Financial Statement Schedules 126 Item 16 Form 10-K Summary 131

Signatures

Signatures 132 2 Table of Contents

Forward-Looking Statements

Forward-Looking Statements This report contains forward-looking statements including, without limitation, statements regarding growth opportunities, including for and in our end markets, new product and service introductions, the position and strength of our businesses, products and services, market demand for and adoption of our products and solutions, the ability of our products and solutions to address customer needs and meet industry requirements, our focus on enhancing our customers' experience, delivering differentiated product solutions and driving productivity improvements, leveraging our product platforms to maximize growth, our investments, including in manufacturing infrastructure, research and development and expanding and improving our applications and solutions portfolios, expanding our position in developing countries and emerging markets, our contributions to our defined benefit plans, our hedging programs and other actions to offset the effects of foreign currency and interest rate movements, our future effective tax rate, unrecognized tax benefits, reimbursement incentives, our ability to satisfy our liquidity requirements, including through cash generated from operations, the potential impact of adopting new accounting pronouncements, indemnification obligations, our sales, our purchase commitments, our capital expenditures, the integration, effects and timing of our acquisitions and other transactions, expense reduction and other results from our restructuring programs and other cost saving initiatives, our stock repurchase program and dividends, macroeconomic and market conditions, including relating to or arising from changes to tariffs, import/export or trade policies, the recovery and health of our end markets, seasonality, mix, future financial results, our operating margin, our geographical diversification, interest rates, inflationary pressures and local regulations and restrictions, that involve risks and uncertainties. Our actual resul

Business

Item 1. Business Overview Agilent Technologies, Inc. ("we", "Agilent" or the "company"), incorporated in Delaware in May 1999, is a global leader in life sciences, diagnostics and applied markets, providing application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. In November 2024, we announced a change in our organizational structure to support our market-focused, customer-centric strategy. Our former Diagnostics and Genomics segment combined with our liquid chromatography and liquid chromatography mass spectrometry instrument platforms to form our new Life Sciences and Diagnostics Markets segment. Our chemistries and supplies, laboratory automation, and software and informatics divisions moved from our former Life Sciences and Applied Markets segment to our Agilent CrossLab segment. The remaining divisions in our former Life Sciences and Applied Markets segment which includes our gas chromatography, gas chromatography mass spectrometry, remarketed instruments, spectroscopy and vacuum divisions formed our new Applied Markets segment. Following this re-organization, we have three business segments - Life Sciences and Diagnostics Markets, Agilent CrossLab and Applied Markets, each of which comprises a reportable segment. All historical financial segment information has been recast to conform to this new presentation. Our Life Sciences and Diagnostics Markets segment is comprised of seven areas of activity. We provide specialty contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level. The Agilent CrossLab segment spans the entire lab with its extensive services and consumables portfolio in addition to software and laboratory automation solutions, which are designe